| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bba842fc4d37dfcaced1b55bc0c91c7c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-233
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-22 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2016-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4461865f4b0fdd8e5bd76ea433ae11c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f63da405bea90a251dc7cd3571108ec1 |
| publicationDate |
2016-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2016150966-A1 |
| titleOfInvention |
Crystalline forms of cabozantinib phosphate and cabozantinib hydrochloride |
| abstract |
The present invention relates to crystalline forms of cabozantinib phosphoric acid salt and cabozantinib hydrochloric acid salt and to a method for their preparation. Furthermore, the invention relates to pharmaceutical compositions comprising said crystalline forms and their use as anti-cancer medicaments. Cabozantinib, i.e. N-{4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl}-N'- (4-fluorophenyl)-l,l-cyclopropanedicarboxamide is represented by the chemical structure: Formula. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11279675-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11731941-B2 |
| priorityDate |
2015-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |